Entasis Therapeutics Holdings Inc. (ETTX)
Symbol Info
Listed Symbol ETTX
Name Entasis Therapeutics Holdings Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $5,000,000
Latest Fiscal EPS $78.69
Price Info
21 Day Moving Average $5.9047
21 Day EMA $5.914240
50 Day Moving Average $6.5839
50 Day EMA $6.226400
200 Day EMA $6.715910
200 Day Moving Average 6.345830
52 Week High $9.25
52 Week Low $3.97
52 Week Change $-22.715101
Alpha -0.035172
Beta 3.0069
Standard Deviation 0.202197
R2 0.594421
Periods 13
Share Information
10 Day Average Volume 10,730
20 Day Average Volume 16,008
30 Day Average Volume 23,108
50 Day Average Volume 20,870
Outstanding Shares 13,134,538
Float Shares 13,112,514
Percent Float 99.83%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 33
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 17,671
Institute Holdings Percent 65.700000
Institute Sold Previous 3 Months 15,215
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 8
Insider Holdings Percent 0.20%
Insider Sold Previous 3 Months -
Insiders Shares Owned 22,024
Price Change
7 Day Price Change $-0.0999999
7 Day Percent Change -1.71%
21 Day Price Change $-0.4000001
21 Day Percent Change -6.50%
30 Day Price Change $-0.0599999
30 Day Percent Change -1.03%
Month To Date Price Change $-0.21
Month To Date Percent -3.52%
90 Day Price Change $-0.51
90 Day Percent Change -8.15%
Quarter To Date $-0.21
Quarter To Date Percent -3.52%
180 Day Price Change $0.250000
180 Day Percent Change 4.55%
200 Day Price Change $-0.7089
200 Day Percent Change -10.98%
Year To Date $1.680000
Year To Date Percent 41.28%
Profile
Description Entasis Therapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company is engaged in the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant Gram-negative bacteria. It has the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its products candidate includes etx2514sul, zoliflodacin, etx0282cpdp, and nbp program.
Details
Issue Type CS
Market Cap $75,523,594
Sec Type
Auditor KPMG LLP
Total Shares Outstanding 13,134,538
CEO Manoussos Perros
Employees 33
Last Audit UQ
Classification
CIK 0001724344
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 35 Gatehouse Drive
Waltham, MA 2451
Website http://www.entasistx.com
Facisimile
Telephone +1 781 810-0120
Email Chris.brinzey@westwicke.com
Key Ratios
Profitability
EBIT Margin -
EBITDA Margin -
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $-
Revenue Per Share $-
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio 0.10
Enterprise Value $20,843,846
Price To Sales -
Price To Free Cash -2.2
PE High Last 5 Years -
Price To Book 1.3
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 1.3
Financial Strength
Total Debt To Equity 0.0
Int Coverage -
Current Ratio 9.1
Leverage Ratio 1.1
Quick Ratio 8.6
Long Term Debt To Capital 0.03
Assets
Receivables Turnover -
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -96.33
Return On Equity -114.53
Return On Capital -112.29
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
ETTX
Entasis Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.